Lupus patients reached remission on an off-the-shelf CAR-T given without chemotherapy first, Fate reports
Fate Therapeutics says FT819, its off-the-shelf CAR-T therapy for lupus, brought three patients to remission or low disease activity without chemotherapy.
Three lupus patients who received FT819, an off-the-shelf CAR-T therapy for lupus, with no chemotherapy beforehand reached remission or low disease activity, Fate Therapeutics said on November 10, 2026. The San Diego company presented the data at ACR Convergence 2026 in Orlando and says the approach fits into routine rheumatology care.
Key points
- Fate says all three of the first patients with lupus outside the kidneys who got FT819 without conditioning chemotherapy responded: two reached DORIS remission and one reached Lupus Low Disease Activity State (LLDAS).
- Across the 36 patients treated as of the August 18, 2026 data cutoff, the company reports no dose-limiting toxicities.
- According to Fate, 12 of the 36 patients (33%) received FT819 as outpatients; eight went home on the day of the infusion and four the next day.
- An estimated 204,295 people in the US met the classification criteria for systemic lupus erythematosus in 2018, according to a meta-analysis of CDC lupus registries.
- Fate's dual-target candidate FT839 is in a Phase 1/2 basket trial called COMPLETE that the company says is open for enrollment.
Why does chemotherapy matter in CAR-T therapy for lupus?
Chemotherapy matters because the published CAR-T results that put lupus into remission followed it, and Fate says dropping it removes a key barrier to patients considering cell therapy. In the case series from Erlangen, Germany, published in the New England Journal of Medicine in February 2024, 15 patients with severe autoimmune disease, 8 of them with lupus, received one infusion of CD19 CAR T cells after preconditioning with fludarabine and cyclophosphamide, and all the patients with lupus reached DORIS remission.
Lupus is not rare. The CDC registry meta-analysis put US prevalence at 72.8 per 100,000, and nine times higher among women than men (128.7 against 14.6 per 100,000). Fate says its chemotherapy-free schedule, which it calls Regimen B, also lets patients stay on the lupus medicines they already take.
What did Fate report for patients treated without chemotherapy?
The company reports that, as of the August 18, 2026 data cutoff, the three patients treated so far under Regimen B kept or deepened their responses as follow-up went on:
| Patient | Reported response |
|---|---|
| Woman, 23, with heart and lung involvement | LLDAS at Months 3, 6 and 9 |
| Woman, 35, treated as an outpatient | SRI-4 response at Months 3 and 6, DORIS remission at Month 9 |
| Woman, 43, with lupus for 24 years, treated as an outpatient | DORIS remission at Month 3; Month 6 not yet reached at the data cutoff |
Fate also reports on fatigue, one of the hardest lupus symptoms to treat. In the 13 patients followed for at least six months, with or without chemotherapy, the median improvement was about 18 points by Month 6, which the company puts at more than four times the minimal clinically important difference, and many patients went from moderate-to-severe fatigue to little or none.
In a two-dose schedule (Regimen C), the first patient, a 57-year-old man who had tried seven earlier therapies, saw his score on the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI-2K) fall from 10 to 2 by Day 29, according to Fate, and was in LLDAS at Months 2 and 3. The second dose was given as an outpatient.
"Across 36 patients, we have seen favorable tolerability with approximately one-third of patients having now received FT819 as outpatient therapy with many discharged on the same-day."
— Bob Valamehr, Ph.D., M.B.A., President and Chief Executive Officer, Fate Therapeutics
What does an off-the-shelf CAR-T mean for rheumatology care?
Our analysis: for rheumatology services, the practical change in Fate's data is logistics. FT819 is made in bulk from a single master stem-cell line and kept in stock, so the company says extra doses are available on demand, and a third of the trial's patients were treated without an overnight stay. Fate says the outpatient safety results were comparable to those in hospital, and that one outpatient was admitted on Day 4 with Grade 2 cytokine release syndrome, which resolved the next day with tocilizumab and supportive care.
Patients point the same way. In focus groups run with the Lupus Foundation of America, five people with active, severe lupus all preferred an off-the-shelf product to one made from their own cells, citing immediate access, shorter hospital stays and lighter conditioning, and most ranked safety first. For lupus nephritis, Fate says its findings support RECLAIM-LN, a Phase 2 study that could support registration.
Related on Healthcare News: five-year results for a single CAR-T infusion in myeloma, and MaxCyte's deal to put cell engineering and its reagents under one supplier.
Frequently asked questions
What is FT819?
FT819 is Fate Therapeutics' CD19-targeting CAR T-cell product candidate. The company makes it from a clonal master induced pluripotent stem cell (iPSC) line, so it is uniform and can be stored for use on demand rather than made for each patient.
What do DORIS, LLDAS, SRI-4 and SLEDAI-2K mean?
DORIS is the Definition of Remission in Systemic Lupus Erythematosus, the same remission criteria the Erlangen series in the New England Journal of Medicine used, and LLDAS is the Lupus Low Disease Activity State. SRI-4 is a response on the Systemic Lupus Erythematosus Responder Index, and SLEDAI-2K is the Systemic Lupus Erythematosus Disease Activity Index, where a lower score means less active disease.
Where were the results presented?
At ACR Convergence 2026, the American College of Rheumatology's annual meeting, held November 6 to 11 in Orlando, Florida, across four presentations from Fate.
Is Fate Therapeutics a public company?
Yes. Fate Therapeutics is listed on Nasdaq under the symbol FATE and is based in San Diego.
Who helped fund the research?
Fate says the work was also funded by the California Institute for Regenerative Medicine, the state's stem cell agency, under grants CLIN2-16303 and CLIN2-20291.
Sources
- Fate Therapeutics Presents New FT819 Data at ACR Convergence 2026 Highlighting Meaningful Clinical Responses in Lupus Without the Use of Conditioning Chemotherapy: press release from Fate Therapeutics via GlobeNewswire, 10 November 2026.
- CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up: Müller and colleagues, New England Journal of Medicine, 22 February 2024.
- Prevalence of Systemic Lupus Erythematosus in the United States: Izmirly and colleagues, meta-analysis of the CDC National Lupus Registries, Arthritis & Rheumatology, June 2021.
- Fate Therapeutics: the company's website.